Evidence map›Paper›PMID 41013605›Full record

ArticleMolecular neurodegeneration2025

A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological features.

Christof Brücke, Mohammed Al-Azzani, Nagendran Ramalingam, Maria Ramón, Rita L Sousa, Fiamma Buratti, Michael Zech, Kevin Sicking, Leslie Amaral, Ellen Gelpi and 10 more

Abstract read
In one paragraph

Article in Molecular neurodegeneration, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. bioRxiv : the preprint server for biology · 2026
    Article
  6. Review
  7. A Novel α-Synuclein K58N Missense Variant in a Patient with Parkinson's Disease.Movement disorders : official journal of the Movement Disorder Society · 2025
    Article
  8. A novel alpha-synuclein K58N missense variant in a patient with Parkinson's disease.medRxiv : the preprint server for health sciences · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors.

Christof Brücke *Department of Neurology, Medical University Vienna, Wien, Austria. christof.bruecke@meduniwien.ac.at.
Mohammed Al-Azzani *Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Nagendran RamalingamAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospitaland, Harvard Medical School, Boston, MA, United States.
Maria RamónDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Rita L SousaDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Fiamma BurattiMax Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario (MPLbioRPartner Laboratoryof theMax Planck Institute for Multidisciplinary Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, UNR-MPINAT), Universidad Nacional de Rosario, Rosario, Argentina.
Michael ZechInstitute of Human Genetics, School of Medicine, Technical University of Munich, Munich, Germany.
Kevin SickingInstitute for Neuropathology, University Medical Center Göttingen, 37077, Göttingen, Germany.
Leslie AmaralDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany.
Ellen GelpiComprehensive Center for Clinical Neurosciences & Mental Health, Medical University of Vienna, Vienna, Austria.
Aswathy ChandranCambridge Institute for Medical Research, University of Cambridge, The Keith Peters Building, Cambridge Biomedical CampusHills Road, Cambridge, CB2 0XY, UK.
Aishwarya AgarwalCambridge Institute for Medical Research, University of Cambridge, The Keith Peters Building, Cambridge Biomedical CampusHills Road, Cambridge, CB2 0XY, UK.
Susana R ChavesCBMA - Centre of Molecular and Environmental Biology, School of Sciences, University of Minho, 4710-057, Braga, Portugal.
Claudio O FernándezMax Planck Laboratory for Structural Biology, Chemistry and Molecular Biophysics of Rosario (MPLbioRPartner Laboratoryof theMax Planck Institute for Multidisciplinary Sciences (MPINAT, MPG). Centro de Estudios Interdisciplinarios, UNR-MPINAT), Universidad Nacional de Rosario, Rosario, Argentina.
Ulf DettmerAnn Romney Center for Neurologic Diseases, Brigham and Women's Hospitaland, Harvard Medical School, Boston, MA, United States.
Janin LautenschlägerCambridge Institute for Medical Research, University of Cambridge, The Keith Peters Building, Cambridge Biomedical CampusHills Road, Cambridge, CB2 0XY, UK.
Markus ZweckstetterDepartment for NMR-Based Structural Biology, Max Planck Institute for Multidisciplinary Sciences, Am Faßberg 11, 37077, Göttingen, Germany.
Rubén Fernández-BusnadiegoInstitute for Neuropathology, University Medical Center Göttingen, 37077, Göttingen, Germany.
Alexander ZimprichDepartment of Neurology, Medical University Vienna, Wien, Austria.
Tiago Fleming OuteiroDepartment of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, University Medical Center Göttingen, Göttingen, Germany. tiago.outeiro@med.uni-goettingen.de.

Funding

Elucidating the Biological Differences Between Distinct Fibrillar and Non-Fibrillar Alpha-Synuclein Inclusions in Human Stem-Cell ModelsR01NS109209 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI KHURANA, VIKRAM · 2020 to 2024
$4.5M
How Serine-129 Phosphorylation Status Affects the Spreading of α-Synuclein Pathology in Vivo: a Study in Knock-in AnimalsRF1NS133979 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF, RAMALINGAM, NAGENDRAN · 2023 to 2023
$2.2M
Polo-like-kinase-2-dependent α-Synuclein Serine-129 Phosphorylation: a Physiological RoleDuring Synaptic ActivityRF1NS122880 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF, RAMALINGAM, NAGENDRAN · 2022 to 2022
$2.1M
Stabilizing native α-synuclein homeostasis to prevent insoluble α-synuclein aggregatesR01NS099328 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2017 to 2021
$1.9M
Polo-like-kinase-2-dependent α-Synuclein Serine-129 Phosphorylation: a Physiological RoleDuring Synaptic ActivityR01NS122880 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Ulf Dettmer, Nagendran Ramalingam · 2025 to 2026
$1.4M
How Serine-129 Phosphorylation Status Affects the Spreading of α-Synuclein Pathology in Vivo: a Study in Knock-in AnimalsR01NS133979 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI Ulf Dettmer, Nagendran Ramalingam · 2026 to 2026
$724k
Contrasting pathomechanisms of membrane versus cytosol alpha-synuclein excessR21NS121826 · NINDS · BRIGHAM AND WOMEN'S HOSPITAL · PI DETTMER, ULF · 2021 to 2021
$505k
Distinguishing α-Synuclein S129 Phosphorylation in Health and Lewy Body DementiaR21AG085401 · NIA · UNIVERSITY OF SOUTH FLORIDA · PI Nagendran Ramalingam · 2024 to 2026
$433k
Addenbrooke's Charitable Trust, Cambridge University Hospitals 900325Aligning Science Across Parkinson's ASAP-000282Bundesministerium für Bildung und Forschung 01GM2302Deutsche Forschungsgemeinschaft EXC 2067/1- 390729940Else Kröner-Fresenius-Stiftung 2022_EKSE.185Leverhulme Trust RPG-2022-257Michael J. Fox Foundation for Parkinson's Research MJFF-022411Michael J. Fox Foundation for Parkinson's Research MJFF-023915NIA NIH HHS R21 AG085401NIH HHS NS121826, NS099328, NS109209, NS122880, NS133979, and AG085401NINDS NIH HHS R01 NS099328NINDS NIH HHS R01 NS109209NINDS NIH HHS R01 NS122880NINDS NIH HHS R01 NS133979NINDS NIH HHS R21 NS121826NINDS NIH HHS RF1 NS122880NINDS NIH HHS RF1 NS133979Royal Society DHF/R1/201228
6 · The paper itself

Abstract

backgroundParkinson's disease (PD) affects millions of people worldwide, but only 5-10% of patients suffer from a monogenic forms of the disease with Mendelian inheritance. SNCA, the gene encoding for the protein alpha-synuclein (aSyn), was the first to be associated with familial forms of PD and, since then, several missense variants and multiplications of the gene have been established as rare causes of autosomal dominant forms of PD. In this study, we report the identification of a novel SNCA mutation in a patient that presented with a complex neurogenerative disorder, and unconventional neuropathological findings. We also performed in depth molecular studies of the effects of the novel aSyn mutation.

methodsA patient carrying the novel aSyn missense mutation and the family members were studied. We present the clinical features, genetic testing-whole exome sequencing (WES), and neuropathological findings. The functional consequences of this aSyn variant were extensively investigated using biochemical, biophysical, and cellular assays.

resultsThe patient exhibited a complex neurodegenerative disease that included generalized myocloni, bradykinesia, dystonia of the left arm and apraxia. WES identified a novel heterozygous SNCA variant (cDNA 40G > A; protein G14R). Neuropathological examination showed extensive atypical aSyn pathology with frontotemporal lobar degeneration (FTLD)-type distribution and nigral degeneration pattern with abundant ring-like neuronal inclusions, and few oligodendroglial inclusions. Sanger sequencing confirmed the SNCA variant in one healthy, 86-year-old parent of the patient suggesting incomplete penetrance. NMR studies suggest that the G14R mutation induces a local structural alteration in aSyn, and lower thioflavin T binding in in vitro fibrillization assays. Interestingly, the G14R aSyn fibers display different fibrillar morphologies than Lewy bodies as revealed by cryo-electron microscopy. Cellular studies of the G14R variant revealed increased inclusion formation, enhanced membrane association, and impaired dynamic reversibility of serine-129 phosphorylation.

conclusionsThe atypical neuropathological features observed, which are reminiscent of those observed for the G51D aSyn variant, suggest a causal role of the SNCA variant with a distinct clinical and pathological phenotype, which is further supported by the properties of the mutant aSyn.

Indexed as

alpha-SynucleinMutation, MissenseParkinson DiseaseBrainExome SequencingHumansPedigreealpha-SynucleinSNCA protein, humanAggregationAlpha-synucleinBradykinesiaDystoniaParkinson´s disease

Identifiers

PMID41013605
PMCPMC12465293

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.